



# Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis

Malcolm S. Duthie, Steven G. Reed

Infectious Disease Research Institute, Seattle, Washington, USA

**ABSTRACT** From experimental models and the analyses of patients, it is well documented that antigen-specific T cells are critical for protection against *Leishmania* infection. Effective vaccines require both targeting to the pathogen and an immune stimulant to induce maturation of appropriate immune responses. While a great number of antigens have been examined as vaccine candidates against various *Leishmania* species, few have advanced to human or canine clinical trials. With emphasis on antigen expression, in this minireview we discuss some of the vaccine platforms that are currently being explored for the development of *Leishmania* vaccines. It is clear that the vaccine platform of choice can have a significant impact upon the level of protection induced by particular antigens, and we provide and highlight some examples for which the vaccine system used has impacted the protective efficacy imparted.

**KEYWORDS** *Leishmania*, adjuvants, protein, vaccine, vector

Haemoflagellate protozoa of the genus *Leishmania* constitute more than 20 species and subspecies of parasites that infect an estimated 12 million people from among a pool of more than 350 million people considered at risk of infection (1, 2, 3). The required interaction with infected sand flies to permit transmission renders leishmaniasis predominantly a disease of the poor, occurring mostly in remote rural villages with poor housing and little or no access to modern health care facilities. Any form of leishmaniasis therefore puts stress on the already limited financial resources of both the affected individual and the community at large (1). Vector-control programs are, however, having an impact, and on the Indian subcontinent a visceral leishmaniasis (VL) elimination target is being met in most areas of endemicity (2). With disruption in control efforts allowing new epidemics in areas of endemicity and the spread of the disease to previously free areas because of migration, tourism, and military activities, however, an effective vaccine remains highly desirable in order to retain/sustain the success of recent efforts (3).

## POTENTIAL FOR VACCINES

The quality of the immune response is critical in determining if *Leishmania* infection manifests disease. The clinical symptoms are also dependent upon the particular *Leishmania* species, which vary in their geographic distributions. Manifestations range from localized, disseminated, diffuse, or recidivate cutaneous leishmaniasis (CL) or mucosal leishmaniasis (ML) to involvement of organs such as liver and spleen in cases of VL (3). CL can arise from infection with any of several *Leishmania* species (i.e., *L. major* or *L. tropica*) and can progress to the gross mucosal tissue destruction observed in ML patients. VL is the most severe form and in South Asia and Africa is caused by infection

Accepted manuscript posted online 17 May 2017

**Citation** Duthie MS, Reed SG. 2017. Not all antigens are created equally: progress, challenges, and lessons associated with developing a vaccine for leishmaniasis. Clin Vaccine Immunol 24:e00108-17. <https://doi.org/10.1128/CVI.00108-17>.

**Editor** Christopher J. Papasian, UMKC School of Medicine

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Malcolm S. Duthie, [mduthie@idri.org](mailto:mduthie@idri.org).

with *L. donovani*, while in the Mediterranean, the Middle East, Latin America, and other parts of Asia, it results from infection with *L. infantum*.

Protection from, and clearance of, *Leishmania* infection is strongly associated with the generation of antigen-specific Th1 responses, knowledge that provides a clear goal for immunization. To target and appropriately skew the anti-*Leishmania* response, vaccines require both pathogen-specific antigens and immune-stimulating molecules to be rendered effective. Whole and genetically attenuated parasites, such as *L. donovani* centrin-deleted parasites (*LdCen1<sup>-/-</sup>*), have undergone trials in both dogs and humans (4–8). Dendritic cell (DC)-based vaccines represent a more refined strategy and have been used in preclinical models. Although financial constraints and the likely difficulties in delivering such vaccines in regions of *Leishmania* endemicity seem to preclude their use in all but a very limited subset of individuals, DC-based vaccines provide further proof of concept supporting the use of more defined vaccines (9).


Our understanding of pattern recognition receptors and adjuvants that can be used in conjunction with recombinant proteins within defined subunit vaccines continues to expand (10–12). A wide variety of adjuvants have been used in *Leishmania* research programs, and the importance of adjuvants within vaccines has been the subject of numerous review articles (13–16). Simultaneous with the progress in adjuvant technologies, advances in bioinformatics and molecular techniques have expanded the number of potential *Leishmania*-specific targets for use within a vaccine (17–19). A considerable number of *Leishmania* antigens have been tested as subunit protein or DNA vaccine candidates against various *Leishmania* species, but variable results have meant that very few antigens have advanced to human or canine clinical trials (20). Factors such as the *Leishmania* source of the target gene, the *Leishmania* species involved in the challenge, the quantity of antigen/vector used, and the frequency and numbers of immunizations all impact our ability to interpret the data beyond their immediate application. In addition, once targets are selected, there are also now a plethora of strategies available with which to ready them for use within a vaccine (21). In this minireview, we discuss the current status of vaccine development for leishmaniasis with emphasis on the impact of the expression/vaccine platforms.

### PURIFIED RECOMBINANT PROTEINS

Native *Leishmania* proteins have been used in either a crude or a purified manner to elicit protective immune responses. *Escherichia coli* and yeast are among the most widely used systems for the production of recombinant proteins (22–24), and bioinformatics has facilitated the production of a variety of recombinant proteins that have been investigated as *Leishmania* vaccine antigen candidates in animal models (15, 20). Key to the use of recombinant proteins is the cost-effectiveness of production, an important consideration when modeling has shown that a cost of \$2 or less per dose for a preventive vaccine would be economically advantageous over the currently available leishmaniasis treatments (25). In addition, recombinant methods also provide the opportunity to manipulate and combine complementary proteins/epitopes in a single gene product.

Our first defined vaccine against leishmaniasis came with the use of *E. coli*-expressed Leish-111f (L111f; LEISH-F1) that joined the *L. major* homologue of eukaryotic thiol-specific antioxidant (TSA), the *L. major* stress-inducible protein-1 (LmSTI1) and the *L. braziliensis* elongation and initiation factor (LeIF) into a chimeric fusion protein. Leish-111f protects mice, hamsters, and rhesus macaques when appropriately formulated with adjuvant, and LEISH-F1 + monophosphoryl lipid A (MPL)-SE was the first defined *Leishmania* vaccine to enter clinical trials, where it demonstrated an excellent safety profile and induced antigen-specific responses (26–29). A second, distinct *E. coli*-derived fusion, LEISH-F3, that combines two components that can protect in animal models of VL, nucleoside hydrolase (NH) and a sterol 24-c-methyltransferase (SMT), has also progressed through phase I clinical trial (30).

The cost-effectiveness of recombinant proteins can also be enhanced by the selection of particular expression platforms. In some instances, yeast (*Saccharomyces cerevi-*



**FIG 1** Influence of expression system on the protective efficacy of immunization with HbR. (A) *Leishmania* HbR was delivered as a DNA vaccine, either as full-length HbR (HbR-FL) or HbR-N coding sequence, intramuscularly into BALB/c mice. The *L. donovani* load per milligram of liver homogenate was determined 60 days after infection (inset shows real-time PCR [RT-PCR] results). Data are shown as mean and standard error of the mean (SEM), with 8 mice per group. (Republished from reference 35 with permission of the publisher.) (B) Mice were injected a total of 3 times with 5 μg *E. coli*-expressed recombinant protein formulated with GLA-SE and then 1 month after the final immunization were infected by intravenous injection of *L. donovani* promastigotes. Mice received either LEISH-F3 (30), protein derived from HbR-N, or a chimeric fusion of F3-HbR. These procedures were conducted in accordance with animal handling protocols approved by the IDRI institutional animal care and use committee. Livers were removed 1 month after parasite inoculation, and burdens were determined by quantitative PCR (qPCR). Data are shown as mean and SEM, with 7 mice per group.

*siae* or *Pichia pastoris*) expression systems provide benefits over *E. coli* expression systems, such as variable folding, glycosylation, or direct secretion into the fermentation media of the target protein as a soluble and stable protein (31, 32). An *E. coli*-expressed *L. donovani* nucleoside hydrolase (LdNH36) surface protein has provided partial protection against *L. donovani* infection in mice (33). Expression of LdNH36 in *P. pastoris* produced LdNH36-Y-WT that was of significantly higher molecular weight than the *E. coli* expressed protein (34). Gel analyses suggested that expression in yeast resulted in several high-mannose glycoforms, whose presence was first reduced by mutating N-linked glycosylation sites located outside the major immunogenic domain from asparagines to serines (LdNH36-dg) and then removed by mutating asparagines to glutamines. The LdNH36-dg2 product was similar in size to the nonglycosylated *E. coli* expressed protein, but the glutamine mutations resulted in increased expression levels. Mice immunized with LdNH36-dg2 did not have high levels of antibodies that inhibited the hydrolase activity of the wild-type LdNH36 (34), although challenge experiments have not been reported.

**DNA VACCINE CONSTRUCTS**

Besides traditional recombinant expression approaches, many antigens have also been investigated in DNA vaccines (20). VL patients possess antibodies against the hemoglobin receptor (HbR) of *Leishmania*, and this protein is conserved across various *Leishmania* strains. Immunization with HbR-DNA generated multifunctional CD4 and CD8 T cells and was reported to provide complete (sterile) protection against *L. donovani* infection in both mice and hamsters (35). Given these findings, we produced recombinant HbR in *E. coli* to examine compatibility with our own vaccine candidates. Surprisingly, unlike our previous data indicating various candidates that retained their protective properties when expressed in *E. coli* (36), we did not observe protection in mice that were immunized with HbR in conjunction with the glucopyranosyl lipid adjuvant-stable emulsion (GLA-SE) (Fig. 1). Furthermore, adding HbR as a component within fusion proteins disrupted their ability to confer protection. We still do not understand why these differences arose, but it is possible that differential processing of epitopes may occur, or some DNA vaccines may target different antigen-presenting cells than protein/adjuvant. While subtle, such changes may be enough to lead to critical variations in the protective efficacy of the respective vaccines.

Fused targets can also be created within DNA vaccines, and seven *Leishmania* genes

(H2A, H2B, H3, H4, A2, KMP11, and HSP70) are encoded within the HisAK70 DNA-vaccine (37). In the VL model, HisAK70-immunized mice exhibited many sterile hepatic granulomas associated with the resolution of hepatic parasite burdens, and in the CL model, spread of parasites to the viscera was completely inhibited in HisAK70-immunized mice. The results suggest that immunization with the HisAK70 DNA may provide a rapid, suitable, and efficient vaccination strategy to confer cross-protective immunity against VL and CL.

### BACTERIAL AND VIRAL VECTORS

In terms of bacterial vectors, *Listeria monocytogenes*, *Mycobacterium bovis* BCG, and *Salmonella enterica* serovar Typhimurium have all been used as vehicles to deliver *Leishmania* targets (20). As an example of this approach, novel *Leishmania* parasite antigens were selected by an *in silico* proteomic approach and expressed in the vector *Salmonella* Typhimurium SL3261. Immunization of mice with individual *Salmonella* vaccine strains expressing the antigens LinJ08.1190 and LinJ23.0410, or a mixture of these bacilli, significantly delayed the progression of *L. major* and enhanced systemic resistance against *L. donovani* (38). These data identify *Salmonella* as another valid vaccine carrier for inducing protection against VL. Given that 2 antigens that were also selected and expressed did not protect, however, this *Salmonella* system may not be appropriate for all antigens.

With regard to viral vectors, the most advanced is a nonreplicative adenovirus vector encoding the A2 antigen (Ad5-A2) that has progressed to *L. infantum* challenge in macaques (39). Using a variety of prime boost schemes involving Ad5-A2 as well as recombinant protein and a plasmid DNA-encoding A2 gene (DNA-A2), parasite burdens in the liver were lower in immunized macaques and correlated with hepatic granuloma resolution and the reduction of clinical symptoms. Considering the importance of both CD4 and CD8 T cells in the control of *Leishmania* infection, we recently generated an adenoviral vector expressing the F3 protein (Ad5-F3) to complement the use of recombinant F3 and investigated immunization strategies with the promise of generating combined protective T-cell responses (40). Overall, a F3+GLA-SE prime/Ad5-F3 boost strategy induced the best combined CD4 and CD8 T cell memory response, although we also found that simultaneous immunization with Ad5-F3 and F3+GLA-SE in a single injection was potent enough to provide protection. As an alternative, although only limited experimental information regarding the effectiveness for use against human pathogens is available, the NYVAC poxvirus vector has also recently been explored (41). Using DNA prime/virus boost protocols, a replication-competent NYVAC expressing LACK (*Leishmania* homologue of mammalian RACKs, the receptors for activated C kinase) (NYVAC-LACK-C7L) induced more polyfunctional CD4 and CD8 T cell responses and greater protection against *L. major* than nonreplicating NYVAC-LACK.

### CLOSING REMARKS

A great number of defined antigens, delivered as recombinant protein in adjuvant, as plasmid DNA, or within vector systems, have provided protection in animal models of leishmaniasis. In an attempt to consolidate information generated across many platforms, we recently selected and expressed 7 candidates as recombinant proteins in *E. coli*. Each recombinant protein was recognized by VL patients and, when formulated with the Th1-potentiating adjuvant GLA-SE, retained its protective efficacy against the challenge of mice with *L. donovani* (36). This indicates the possibility of combining candidates that have advanced in diverse vaccine platforms. It is clear, however, that the vaccine platform of choice can have a significant impact upon the level of protection induced and in some instances can negate protection altogether. Thus, without actually generating independent results, vaccine developers must be cautious when navigating through the existing data and between the platforms (Table 1). On the positive side, as is seen most clearly with viral vectors, exploring interactions between

**TABLE 1** Impact of production system on protective efficacy of *Leishmania*-specific vaccine targets<sup>a</sup>

		Vaccine antigen system									
		recombinant		DNA		bacteria					
						Salmonella		Listeria		BCG	
LACK				infantum (42)							
				donovani (43)							
				chagasi (44)	chagasi (45)						
		major (46)		major (47-49)				major (50)			
		amazonensis (51)		amazonensis (51)							
		braziliensis (52)		braziliensis (52)							
gp63				infantum (53)		donovani (54)					
		major (55)	major (56)	major (57)	major (58)	major (59)	major (60)		major (61)	major (62)	
				mexicana (63, 64)					mexicana (62)	mexicana (65)	

protection	none	partial	strong	complete
------------	------	---------	--------	----------

<sup>a</sup>Examples of the various data generated for the *Leishmania*-specific components, LACK and gp63, across some of the vaccine systems used are shown. The protection levels are indicated by the color scheme and were obtained from the review by Costa et al. (20); the pertinent citations (42–65) are indicated in parentheses. *L. donovani*, *L. chagasi*, and *L. infantum* cause VL; *L. braziliensis*, *L. major*, *L. mexicana*, and *L. amazonensis* cause CL or ML.

these technologies has the potential to yield regimens that augment, complement, or synergize each other to yield a robust protective regimen.

**ACKNOWLEDGMENTS**

This work was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award R01AI025038. Additional program support came from the Bill and Melinda Gates Foundation under grant 631.

The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Malcolm S. Duthie and Steven G. Reed are coinventors of a patent for leishmaniasis vaccine development.

**REFERENCES**

- Okwor I, Uzonna J. 2016. Social and economic burden of human leishmaniasis. *Am J Trop Med Hyg* 94:489–493. <https://doi.org/10.4269/ajtmh.15-0408>.
- WHO. 2005. Regional strategic framework for elimination of kala-azar from the South-East Asian Region (2005-2015). World Health Organization, New Delhi, India.
- Engwerda CR, Matlashewski G. 2015. Development of *Leishmania* vaccines in the era of visceral leishmaniasis elimination. *Trans R Soc Trop Med Hyg* 109:423–424. <https://doi.org/10.1093/trstmh/trv039>.
- Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasser K, Modabber F, Sharifi I, Khalil EA, Bernal ID, Antunes CM, Smith PG. 2009. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. *Vaccine* 27:4747–4753. <https://doi.org/10.1016/j.vaccine.2009.05.084>.
- Mohebbi M, Khamesipour A, Mobeidi I, Zarei Z, Hashemi-Fesharki R. 2004. Double-blind randomized efficacy field trial of alum precipitated autoclaved *Leishmania major* vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. *Vaccine* 22: 4097–4100. <https://doi.org/10.1016/j.vaccine.2004.03.058>.
- Selvapandiyana A, Dey R, Nysten S, Duncan R, Sacks D, Nakhasi HL. 2009. Intracellular replication-deficient *Leishmania donovani* induces long lasting protective immunity against visceral leishmaniasis. *J Immunol* 183: 1813–1820. <https://doi.org/10.4049/jimmunol.0900276>.
- Fiuzza JA, Santiago Hda C, Selvapandiyana A, Gannavaram S, Ricci ND, Bueno LL, Bartholomeu DC, Correa-Oliveira R, Nakhasi HL, Fujiwara RT. 2013. Induction of immunogenicity by live attenuated *Leishmania donovani* centrin deleted parasites in dogs. *Vaccine* 31:1785–1792. <https://doi.org/10.1016/j.vaccine.2013.01.048>.
- Fiuzza JA, Gannavaram S, Santiago Hda C, Selvapandiyana A, Souza DM, Passos LS, de Mendonca LZ, Lemos-Giunchetti DDS, Ricci ND, Bartholomeu DC, Giunchetti RC, Bueno LL, Correa-Oliveira R, Nakhasi HL, Fujiwara RT. 2015. Vaccination using live attenuated *Leishmania donovani* centrin deleted parasites induces protection in dogs against *Leishmania infantum*. *Vaccine* 33:280–288. <https://doi.org/10.1016/j.vaccine.2014.11.039>.
- Bagirova M, Allahverdiyev AM, Abamor ES, Ullah I, Cosar G, Aydogdu M, Senturk H, Ergenoglu B. 2016. Overview of dendritic cell-based vaccine development for leishmaniasis. *Parasite Immunol* 38:651–662. <https://doi.org/10.1111/pim.12360>.
- Degn SE, Thiel S. 2013. Humoral pattern recognition and the complement system. *Scand J Immunol* 78:181–193. <https://doi.org/10.1111/sji.12070>.

11. Ray A, Cot M, Puzo G, Gilleron M, Nigou J. 2013. Bacterial cell wall macroamphiphiles: pathogen-/microbe-associated molecular patterns detected by mammalian innate immune system. *Biochimie* 95:33–42. <https://doi.org/10.1016/j.biochi.2012.06.007>.
12. Carter D, Fox CB, Day TA, Guderian JA, Liang H, Rolf T, Vergara J, Sagawa ZK, Iretton G, Orr MT, Desbien A, Duthie MS, Coler RN, Reed SG. 2016. A structure-function approach to optimizing TLR4 ligands for human vaccines. *Clin Transl Immunology* 5:e108. <https://doi.org/10.1038/cti.2016.63>.
13. Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR. 2013. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. *Vaccine* 31:735–749. <https://doi.org/10.1016/j.vaccine.2012.11.068>.
14. Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. 2012. Adjuvants for *Leishmania* vaccines: from models to clinical application. *Front Immunol* 3:144. <https://doi.org/10.3389/fimmu.2012.00144>.
15. Duarte MC, Lage DP, Martins VT, Chavez-Fumagalli MA, Roatt BM, Menezes-Souza D, Goulart LR, Soto M, Tavares CA, Coelho EA. 2016. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. *Rev Soc Bras Med Trop* 49:398–407. <https://doi.org/10.1590/0037-8682-0120-2016>.
16. Mutiso JM, Macharia JC, Gicheru MM. 2010. A review of adjuvants for *Leishmania* vaccine candidates. *J Biomed Res* 24:16–25. [https://doi.org/10.1016/S1674-8301\(10\)60004-8](https://doi.org/10.1016/S1674-8301(10)60004-8).
17. Alcolea PJ, Alonso A, Larraga V. 2016. Rationale for selection of developmentally regulated genes as vaccine candidates against *Leishmania infantum* infection. *Vaccine* 34:5474–5478. <https://doi.org/10.1016/j.vaccine.2016.08.081>.
18. de Freitas e Silva R, Ferreira LF, Hernandez MZ, de Brito MEF, de Oliveira BC, da Silva AA, de-Melo-Neto OP, Rezende AM, Pereira VR. 2016. Combination of in silico methods in the search for potential CD4(+) and CD8(+) T cell epitopes in the proteome of *Leishmania braziliensis*. *Front Immunol* 7:327. <https://doi.org/10.3389/fimmu.2016.00327>.
19. Seyed N, Taheri T, Rafati S. 2016. Post-genomics and vaccine improvement for *Leishmania*. *Front Microbiol* 7:467. <https://doi.org/10.3389/fmicb.2016.00467>.
20. Costa CH, Peters NC, Maruyama SR, de Brito EC, Jr, Santos IK. 2011. Vaccines for the leishmaniases: proposals for a research agenda. *PLoS Negl Trop Dis* 5:e943. <https://doi.org/10.1371/journal.pntd.0000943>.
21. Legastelois I, Buffin S, Peubez I, Mignon C, Sodoyer R, Werle B. 2017. Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules. *Hum Vaccin Immunother* 13:947–961. <https://doi.org/10.1080/2164551520161260795:1-15>.
22. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A. 2009. Microbial factories for recombinant pharmaceuticals. *Microb Cell Fact* 8:17. <https://doi.org/10.1186/1475-2859-8-17>.
23. Graumann K, Premstaller A. 2006. Manufacturing of recombinant therapeutic proteins in microbial systems. *Biotechnol J* 1:164–186. <https://doi.org/10.1002/biot.200500051>.
24. Josefsberg JO, Buckland B. 2012. Vaccine process technology. *Biotechnol Bioeng* 109:1443–1460. <https://doi.org/10.1002/bit.24493>.
25. Bacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi ME, Valenzuela JG, Lee BY. 2013. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. *Vaccine* 31:480–486. <https://doi.org/10.1016/j.vaccine.2012.11.032>.
26. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. *Vaccine* 20:3292–3303. [https://doi.org/10.1016/S0264-410X\(02\)00302-X](https://doi.org/10.1016/S0264-410X(02)00302-X).
27. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. *Infect Immun* 75:4648–4654. <https://doi.org/10.1128/IAI.00394-07>.
28. Campos-Neto A, Porrozzzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi G, Jr. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. *Infect Immun* 69:4103–4108. <https://doi.org/10.1128/IAI.69.6.4103-4108.2001>.
29. Velez ID, Gilchrist K, Martinez S, Ramirez-Pineda JR, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM. 2009. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. *Vaccine* 28:329–337. <https://doi.org/10.1016/j.vaccine.2009.10.045>.
30. Coler RN, Duthie MS, Hofmeyer KA, Guderian J, Jayashankar L, Vergara J, Rolf T, Misquith A, Laurance JD, Raman VS, Bailor HR, Cauwelaert ND, Reed SJ, Vallur A, Favila M, Orr MT, Ashman J, Ghosh P, Mondal D, Reed SG. 2015. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. *Clin Transl Immunol* 4:e35. <https://doi.org/10.1038/cti.2015.6>.
31. Porro D, Gasser B, Fossati T, Maurer M, Branduardi P, Sauer M, Mattanovich D. 2011. Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems? *Appl Microbiol Biotechnol* 89:939–948. <https://doi.org/10.1007/s00253-010-3019-z>.
32. Salgado D, Fischer R, Schillberg S, Twyman RM, Rasche S. 2014. Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D. *Front Immunol* 5:623. <https://doi.org/10.3389/fimmu.2014.00623>.
33. McAtee CP, Seid CA, Hammond M, Hudspeth E, Keegan BP, Liu Z, Wei J, Zhan B, Arjona-Sabido R, Cruz-Chan V, Dumonteil E, Hotez PJ, Bottazzi ME. 2017. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from *Leishmania donovani*, a vaccine candidate for preventing cutaneous leishmaniasis. *Protein Expr Purif* 130:129–136. <https://doi.org/10.1016/j.pep.2016.10.008>.
34. Hudspeth EM, Wang Q, Seid CA, Hammond M, Wei J, Liu Z, Zhan B, Pollet J, Heffernan MJ, McAtee CP, Engler DA, Matsunami RK, Strych U, Asojo OA, Hotez PJ, Bottazzi ME. 2016. Expression and purification of an engineered, yeast-expressed *Leishmania donovani* nucleoside hydrolase with immunogenic properties. *Hum Vaccin Immunother* 12:1707–1720.
35. Guha R, Gupta D, Rastogi R, Vikram R, Krishnamurthy G, Bimal S, Roy S, Mukhopadhyay A. 2013. Vaccination with *Leishmania* hemoglobin receptor-encoding DNA protects against visceral leishmaniasis. *Sci Transl Med* 5:202ra121. <https://doi.org/10.1126/scitranslmed.3006406>.
36. Duthie MS, Favila M, Hofmeyer KA, Tutterrow YL, Reed SJ, Laurance JD, Picone A, Guderian J, Bailor HR, Vallur AC, Liang H, Mohamath R, Vergara J, Howard RF, Coler RN, Reed SG. 2016. Strategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasis. *Vaccine* <https://doi.org/10.1016/j.vaccine.2016.04.067>.
37. Dominguez-Bernal G, Horcajo P, Orden JA, Ruiz-Santa-Quiteria JA, De La Fuente R, Ordóñez-Gutiérrez L, Martínez-Rodrigo A, Mas A, Carrion J. 2015. HisAK70: progress towards a vaccine against different forms of leishmaniasis. *Parasit Vectors* 8:629. <https://doi.org/10.1186/s13071-015-1246-y>.
38. Schroeder J, Brown N, Kaye P, Aebischer T. 2011. Single dose novel *Salmonella* vaccine enhances resistance against visceralizing *L. major* and *L. donovani* infection in susceptible BALB/c mice. *PLoS Negl Trop Dis* 5:e1406. <https://doi.org/10.1371/journal.pntd.0001406>.
39. Grimaldi G, Jr, Teva A, Porrozzzi R, Pinto MA, Marchevsky RS, Rocha MG, Dutra MS, Bruna-Romero O, Fernandes AP, Gazzinelli RT. 2014. Clinical and parasitological protection in a *Leishmania infantum*-macaque model vaccinated with adenovirus and the recombinant A2 antigen. *PLoS Negl Trop Dis* 8:e2853. <https://doi.org/10.1371/journal.pntd.0002853>.
40. Hofmeyer KA, Duthie MS, Laurance JD, Favila MA, Van Hoven N, Coler RN, Reed SG. 2016. Optimizing immunization strategies for the induction of antigen-specific CD4 and CD8 T cell responses for protection against intracellular parasites. *Clin Vaccine Immunol* 23:785–794. <https://doi.org/10.1128/CVI.00251-16>.
41. Sanchez-Sampedro L, Mejias-Perez E, Sorzano COS, Najera JL, Esteban M. 2016. NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis. *Virus Res* 220:1–11. <https://doi.org/10.1016/j.virusres.2016.03.007>.
42. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. 2005. Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. *Infect Immun* 73:5286–5289. <https://doi.org/10.1128/IAI.73.8.5286-5289.2005>.
43. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. 2001. *Leishmania donovani* p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. *Infect Immun* 69:4719–4725. <https://doi.org/10.1128/IAI.69.8.4719-4725.2001>.
44. Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, Rossi-Bergmann B. 2007. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. *Vaccine* 25:2168–2172. <https://doi.org/10.1016/j.vaccine.2006.11.060>.
45. Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, Tavares CA, Fernandes AP, Afonso LC, Rezende SA. 2005. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against *Leishmania chagasi*

- intravenous challenge. *Parasitol Res* 98:67–74. <https://doi.org/10.1007/s00436-005-0008-8>.
46. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, Waldmann R, Locksley RM, Glaichenhaus N. 1995. Expression cloning of a protective *Leishmania* antigen. *Science* 268:563–566. <https://doi.org/10.1126/science.7725103>.
  47. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. 2004. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to *L. major*. *Vaccine* 22:1631–1639. <https://doi.org/10.1016/j.vaccine.2003.10.046>.
  48. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with *Leishmania major*. *J Exp Med* 186:1137–1147. <https://doi.org/10.1084/jem.186.7.1137>.
  49. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, Lucas P, Larraga V, Esteban M. 2002. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the *Leishmania infantum* P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. *Vaccine* 20:1226–1231. [https://doi.org/10.1016/S0264-410X\(01\)00427-3](https://doi.org/10.1016/S0264-410X(01)00427-3).
  50. Soussi N, Milon G, Colle JH, Mougneau E, Glaichenhaus N, Goossens PL. 2000. *Listeria monocytogenes* as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of *Leishmania major*. *Infect Immun* 68:1498–1506. <https://doi.org/10.1128/IAI.68.3.1498-1506.2000>.
  51. Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B. 2004. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. *Infect Immun* 72:4521–4527. <https://doi.org/10.1128/IAI.72.8.4521-4527.2004>.
  52. Salay G, Dorta ML, Santos NM, Mortara RA, Brodskyn C, Oliveira CI, Barbieri CL, Rodrigues MM. 2007. Testing of four *Leishmania* vaccine candidates in a mouse model of infection with *Leishmania (Viannia) braziliensis*, the main causative agent of cutaneous leishmaniasis in the New World. *Clin Vaccine Immunol* 14:1173–1181. <https://doi.org/10.1128/CI.00060-07>.
  53. Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, Sanchez-Robert E, Francino O, Alberola J. 2007. Vaccination with plasmid DNA encoding KMP11, TRYP, LACK and GP63 does not protect dogs against *Leishmania infantum* experimental challenge. *Vaccine* 25:7962–7971. <https://doi.org/10.1016/j.vaccine.2007.08.023>.
  54. McSorley SJ, Xu D, Liew FY. 1997. Vaccine efficacy of *Salmonella* strains expressing glycoprotein 63 with different promoters. *Infect Immun* 65:171–178.
  55. Rivier D, Bovay P, Shah R, Didisheim S, Mauel J. 1999. Vaccination against *Leishmania major* in a CBA mouse model of infection: role of adjuvants and mechanism of protection. *Parasite Immunol* 21:461–473. <https://doi.org/10.1046/j.1365-3024.1999.00244.x>.
  56. Handman E, Button LL, McMaster RW. 1990. *Leishmania major*: production of recombinant gp63, its antigenicity and immunogenicity in mice. *Exp Parasitol* 70:427–435. [https://doi.org/10.1016/0014-4894\(90\)90127-X](https://doi.org/10.1016/0014-4894(90)90127-X).
  57. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, Vogel JC. 1998. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. *Hum Gene Ther* 9:1899–1907. <https://doi.org/10.1089/hum.1998.9.13-1899>.
  58. Xu D, Liew FY. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of *L. major*. *Immunology* 84:173–176.
  59. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. 1990. Oral *Salmonella typhimurium* (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. *J Immunol* 145:2281–2285.
  60. Xu D, McSorley SJ, Chatfield SN, Dougan G, Liew FY. 1995. Protection against *Leishmania major* infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated *Salmonella typhimurium* (AroA- AroD-). *Immunology* 85:1–7.
  61. Abdelhak S, Louzir H, Timm J, Blel L, Benlasfar Z, Lagranderie M, Gheorghiu M, Dellagi K, Gicquel B. 1995. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against *Leishmania major* infection in BALB/c mice. *Microbiology* 141:1585–1592.
  62. Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the *Leishmania* surface protein gp63. *Proc Natl Acad Sci U S A* 90:11473–11477. <https://doi.org/10.1073/pnas.90.24.11473>.
  63. Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J, Ramirez-Sierra MJ, Valencia-Pacheco G, Flores-Serrano A, Canto-Lara S, Arjona-Torres A. 2000. Comparative study of DNA vaccines encoding various antigens against *Leishmania mexicana*. *Dev Biol (Basel)* 104:135–141.
  64. Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM. 2003. DNA vaccines induce partial protection against *Leishmania mexicana*. *Vaccine* 21:2161–2168. [https://doi.org/10.1016/S0264-410X\(02\)00769-7](https://doi.org/10.1016/S0264-410X(02)00769-7).
  65. Gonzalez CR, Noriega FR, Huerta S, Santiago A, Vega M, Paniagua J, Ortiz-Navarrete V, Isibasi A, Levine MM. 1998. Immunogenicity of a *Salmonella typhi* CVD 908 candidate vaccine strain expressing the major surface protein gp63 of *Leishmania mexicana mexicana*. *Vaccine* 16:1043–1052. [https://doi.org/10.1016/S0264-410X\(97\)00267-3](https://doi.org/10.1016/S0264-410X(97)00267-3).

**Malcolm S. Duthie** graduated with a B.Sc. degree in Immunology from the University of Glasgow, Scotland, followed by a Ph.D. in Medical Microbiology from the University of Edinburgh, Scotland. Following postdoctoral work at the University of Washington, Seattle, he joined the Infectious Disease Research Institute (IDRI) in 2002. In his role as a Senior Scientist at IDRI, Dr. Duthie's main research interests lie in determining how host/pathogen interactions can be beneficially manipulated to generate tools for practical application within disease control programs. Dr. Duthie works with an extensive network of collaborators in several countries to identify vaccine candidates and develop new diagnostic tools to improve the control of neglected tropical diseases, with a current focus on leprosy and leishmaniasis.



**Steven G. Reed** graduated with a Ph.D. in Microbiology and Immunology from the University of Montana before being appointed Scientist of the National Institute of Amazon Research in Manaus, Brazil, where he directed research on tropical diseases. This research continued in Dr. Reed's capacity as manager of the Cornell-Bahia program of international medicine. Among multiple advisory positions, he has served as a member of diagnostic and vaccine steering committees of the World Health Organization. In addition to founding several biotechnology companies, in 1993 Dr. Reed established the Infectious Disease Research Institute (IDRI), where he currently serves as President and Chief Executive Officer. Dr. Reed's research interests have focused on the immunology of intracellular pathogens, with the intent of developing vaccines and diagnostics that can be made widely available in developing countries.

